PepVault
/ database / Neuroprotective

ARA-290

Also: Cibinetide · EPO-derived peptide

EPO-derived peptide for small-fiber neuropathy and inflammatory nerve pain.

Evidence
emerging
Legal status
research only
Half-life
~2 minutes (active signaling persists longer)
Routes
subq
View on Limitless LifeAdd to compare
What it is

ARA-290 (cibinetide) was engineered to retain EPO's tissue-protective signaling while removing its red-blood-cell-stimulating effects. Phase II data in sarcoidosis-related small-fiber neuropathy showed meaningful improvements in pain and corneal nerve fiber density. Development by Araim Pharmaceuticals has been intermittent.

Mechanism

11-amino-acid peptide derived from erythropoietin. Activates the innate-repair receptor (IRR) without erythropoietic effects — anti-inflammatory and neuroprotective.

Outcomes it's matched to
Safety

Well tolerated in trials, including no measurable change to hematocrit at therapeutic doses.

  • Active malignancy (theoretical)
Legal context

Investigational. Not currently approved anywhere.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault